Bioceres Crop Solutions Corp. · NASDAQ:BIOX
Bioceres Crop Solutions — Investor Presentation (December 2022)
19 slides from Bioceres Crop Solutions's investor presentation, December 2022

Slide 1: Investor Presentation
BIOCERES CROP SOLUTIONS Investor Presentation • NASDAQ: BIOX 02 03 DECEMBER 2022 04 NASDAQ: BIOX | DEC 2022

Slide 2: Disclaimer
BIOCERES CROP SOLUTIONS Disclaimer This Presentation is for informational purposes only and does not constitute an offer or invitation to sell, a solicitation of Financial Information Presentation an offer to buy, or a recommendation to purchase any equity, assets, business, debt or other financial

Slide 3: Corporate Overview
BIOCERES CROP SOLUTIONS Corporate Overview We are a fully-integrated provider of crop productivity technologies designed to enable the transition of agriculture towards carbon neutrality $382M Revenues 1 Grower and consumer-oriented solutions $73M Adj. EBITDA 2 02 03 Unique portfolio of highly effic

Slide 4: History
BIOCERES CROP SOLUTIONS History 44 years of experience utilizing multiple technological approaches to develop and commercialize products that enhance crop quality and productivity Trigall Genetics Bioceres Crop 03 and Verdeca Solutions created and JVs created Bioceres listed NYSE (BIOX) Bioceres 04

Slide 5: Science-driven solutions that promote climate-smart outcomes
BIOCERES CROP SOLUTIONS Science-driven solutions that promote We develop and commercialize products that climate-smart guarantee the health and food security of the future, accelerating the transition to carbon- outcomes neutral agriculture. 04 Enhance sequestration of GHGs 05 Agriculture faces a do

Slide 6: Product Portfolio
BIOCERES CROP SOLUTIONS Product Portfolio Unique portfolio with low environmental impact technologies and multiple levers of growth Operational Crop Protection Crop Nutrition Seed and Integrated Products Business Segment 05 Pest control Micro-beaded Crop health 06 molecules and Seed Seed traits & Pr

Slide 7: The HB4 Technology Performance
BIOCERES CROP SOLUTIONS The HB4 Technology Performance The only available technology for drought tolerance in soy-wheat cropping systems Soy Wheat 06 07 08 09 NASDAQ: BIOX | DEC 2022 Control Control +13% impact in yields +19.5% impact in yields

Slide 8: HB4 Value Creation to Growers
BIOCERES CROP SOLUTIONS HB4 Value Creation to Growers Total addressable market 07 08 09 10 Additional value created by HB4 1 Total addressable market 2 Share of total market 3 Soy High Low ~30-35M ha ~35-40% NASDAQ: BIOX | DEC 2022 High Low ~2.5-3M ha ~30-35% Wheat 1 Analysis comprises average histo

Slide 9: HB4 Market Approvals: Production - Food & Feed
BIOCERES CROP SOLUTIONS HB4 Market Approvals: Production - Food & Feed Access and Regulatory Soy Wheat Status Argentina Argentina 08 Brazil Brazil ¹ 09 USA Colombia ¹ 10 Paraguay Australia ² 11 Canada New Zealand ² China ¹ USA ¹ South Africa ¹ Nigeria ¹ NASDAQ: BIOX | DIC 2022 South Africa ¹ Regulat

Slide 10: Upcoming Pipeline Commercial Launches
BIOCERES CROP SOLUTIONS Upcoming Pipeline Commercial Launches Portfolios complement and extend visible organic growth potential Key upcoming WHEAT & SOY MBI 306 BIOHERBICIDES 09 commercial Strong synergies with bio- Unlocks 100% bio-based seed Three leads with blockbuster potential based seed treatm

Slide 11: Global Reach
BIOCERES CROP SOLUTIONS Global Reach 40+ Strong commercial Countries with commercial footprint across key presence agricultural markets 10 60% 11 12 Global arable land coverage 13 50+ NASDAQ: BIOX | DIC 2022 Global commercial agreements in place Key Manufacturing Facilities Subsidiary Presence Comme

Slide 12: Company Performance
BIOCERES CROP SOLUTIONS Company Performance Proven track-record in delivering solid financial performance Revenues ($Million)1 LTM 1Q23 | Revenues and Gross Margins (%) 11 382 12 319 13 195 +32% 14 197 382 132 174 +42% +49% 149 134 NASDAQ: BIOX | DEC 2022 54 +63% FY18 FY19 FY20 FY21 FY22 LTM 1Q23 Cr

Slide 13: Sustained Adj. EBITDA Growth
BIOCERES CROP SOLUTIONS Sustained Adj. EBITDA Growth 73 ($ Million) 62 47 50 41 12 13 14 22 15 LTM FY18 FY19 FY20 FY21 FY22 NASDAQ: BIOX | DEC 2022 1Q23 Adjusted EBITDA Margin (%) 2 16% 25% 27% 24% 19% 19% 1 FY18-FY22 financials presented correspond to As Reported Adj. EBITDA excluding HB4 pre-launc

Slide 14: Balance Sheet and Cash Position
BIOCERES CROP SOLUTIONS Balance 2.78x Net Debt Sheet Adj. EBITDA and Cash ($ Million) 227.9 Position 153.1 13 14 15 16 101.3 Current Debt 74.7 Non-Current Debt 51.3 NASDAQ: BIOX | DIC 2022 Cash & Equivalent Subsequent Cash & Equivalent 1Q23 1 Cash & Equivalents includes other cash management short-t

Slide 15: Exhibits
BIOCERES CROP SOLUTIONS 14 Exhibits 15 16 17 NASDAQ: BIOX | DIC 2022

Slide 16: Unaudited Consolidated Statement of Comprehensive Income
BIOCERES CROP SOLUTIONS Unaudited Consolidated Statement of Comprehensive Income Three-month period Three-month period ended 09/30/2022 ended 09/30/2021 Total revenue 127,105,318 66,906,245 Cost of sales (75,675,878) (37,882,453) Gross profit 51,429,440 29,023,792 % Gross profit 40% 43% Operating ex

Slide 17: Unaudited Consolidated Statement of Financial Position
BIOCERES CROP SOLUTIONS Unaudited Consolidated Statement of Financial Position ASSETS 09/30/2022 06/30/2022 LIABILITIES 09/30/2022 06/30/2022 CURRENT ASSETS CURRENT LIABILITIES Cash and cash equivalents 47,387,568 33,475,266 Trade and other payables 138,810,191 125,849,620 Other financial assets 3,9

Slide 18: Management
BIOCERES CROP SOLUTIONS Management Federico Trucco, Chief Executive Officer Federico originally joined Bioceres as a research leader for one of its R&D projects, then a project management firm in the ag-biotech space. Federico then helped organize and initially run Bioceres’ biotech center, a state-

Slide 19: Contact Us
BIOCERES CROP SOLUTIONS Contact Us Investor Relations Investorrelations@biocerescrops.com (54) 0341 4861100 Investors.biocerescrops.com NASDAQ: BIOX | DEC 2022
Source: Internet Archive copy of s26.q4cdn.com
More decks from Bioceres Crop Solutions Corp.
Q4 2026 Earnings Presentation17 slides · Sep 15, 2026
Q3 2026 Earnings Presentation16 slides · May 12, 2026
Q1 2026 Earnings Presentation13 slides · Nov 13, 2025
Q4 2025 Earnings Presentation16 slides · Sep 9, 2025
Q3 2025 Earnings Presentation18 slides · May 21, 2025
Q2 2025 Earnings Presentation20 slides · Feb 12, 2025